Fig. 6
Exogenously administered LTC4 induces a rapid platelet-dependent increase in lung IL-33 and type 2 cytokine production. OVA-sensitized WT mice received three aerosol challenges with 0.1% OVA. Some mice received intranasal administration of LTC4 (2.2 nmol) preceding each OVA challenge by 12 h. The indicated mice were then treated with a platelet-depleting anti-CD41 Ab or isotype one day before receiving either an additional intranasal dose of LTC4 or PBS control 1 h before euthanasia. a BAL fluid total cells (left) and eosinophils (right). b BAL fluid levels of HMGB1 (top row), CXCL7 and TXB2 (middle row) from the same mice as in a. c Levels of IL-33 protein detected in homogenates from the lungs of mice in the indicated groups. d Levels of IL-5 and IL-13 from the same homogenates as in c. e Numbers of ILC2s detected in single cell suspensions from the same mice. f Western blots of whole lung lysates showing changes in CD61 as a surrogate for platelet recruitment. Results in a–e are from 10 mice per group from two independent experiments. Results in f are from a representative blot (left), with quantitative densitometry (right) from five mice per group
